Pharmafile Logo
Pharmafocus logo
Advanced Search

Adcetris

Showing 5 posts of 5 posts found.

takeda_usa_pharmaceuticals_u

Takeda’s Adcetris secures expanded approval in Europe for untreated CD30+ Stage IV Hodgkin lymphoma

February 14, 2019
Sales and Marketing Adcetris, Cancer, Europe, Hodgkin lymphoma, Takeda, pharma

Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously …

News
takeda_tokyo_hq

Old CDF drug not recommended in initial NICE guidance due to lack of evidence

August 10, 2016
Research and Development, Sales and Marketing Adcetris, Cancer Drugs Fund, NICE, Takeda, hodgkin's lymphoma

The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Takeda’s Adectris (brentuximab vedotin), despite …

News
takeda_tokyo_hq

Phase III success for Takeda in lymphoma drug

August 1, 2016
Manufacturing and Production, Research and Development Adcetris, Seattle Genetics, Takeda, lymphoma

Takeda Oncology and Seattle Generic have announced new Phase III data for trial drug, Adcetris (brentuximab vedotin), in patients with …

News
Takeda image

Takeda eyes new drug licences following positive blood cancer studies

December 11, 2014
Research and Development, Sales and Marketing Adcetris, Takeda, Velcade, ash, bortezomib, brentuximab vedotin, hematology

Takeda is bringing its biotech arm in-house to create a global oncology business unit, which it says will drive forward …

News

Blood cancer drug Adcetris approved by FDA

August 24, 2011
Sales and Marketing Adcetris, Cancer, Seattle Genetics, lymphoma

The FDA has approved Seattle Genetics’ blood cancer drug Adcetris for two forms of lymphoma. Adcetris (brentuximab vedotin) can now …

News

Latest content

Regeneron and Mammoth Biosciences announce CRISPR collaboration

April 26, 2024

ANGLE signs commercial agreement with AstraZeneca

April 26, 2024

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024